๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenzhen
Clinical trial register · China

Clinical Trials in Shenzhen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shenzhen Geno-Immune Medical Institute43 Beijing Biotech32 Sun Yat-sen University23 Bristol-Myers Squibb19 Shenzhen University General Hospital11
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shenzhen

576 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes
NCT07599046Obesity Type 2 Diabetes Mellitus
DrugsFecal Microbiota Transplantation·Semaglutide
Eighth Affiliated Hospital, Sun Yat-sen University
Not applicable
20
Shenzhen
2026-04-30
Recruiting
Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
NCT07563179Acute Myeloid Leukemia, Relapse/Recurrence
Shenzhen University General Hospital
Phase 2
10
Shenzhen
2026-04-21
By invitation
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
NCT07618624Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
DrugsPemetrexed·Paclitaxel
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2026-04-20
Not yet open
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
NCT07585747Follicular Lymphoma
DrugsTafasitamab·Orelabrutinib·Lenalidomide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
27
Shenzhen, Zhengzhou, Nanchang, Jinan, Tianjin
2026-04-15
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Beijing, Hangzhou, Shanghai, Shenzhen
2026-04-14
Recruiting
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
NCT07541521Stage IIB-III NSCLC, Sleeve Lobectomy, Robotic Surgery, Neoadjuvant Chemoimmunotherapy
Shanghai Chest Hospital
Observational
100
Fuzhou, Guangzhou, Shenzhen, Nanjing, Qingdao, Tianjing, Shanghai
2026-04-13
Not yet open
Effects and Mechanisms of Dietary Carbohydrate Intake and Quality on Glucose and Lipid Metabolism
NCT07533513Metabolic Syndrome (MetS), Metabolic Syndrome Risk Factors
Sun Yat-sen University
Not applicable
20
Shenzhen
2026-04-13
Active, closed
A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents
NCT07472725Diabetes Mellitus, Type 2
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
102
Shenzhen, Nanjing
2026-04-11
Not yet open
Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis
NCT07451665Takayasu Arteritis (TAK)
DrugsIvarmacitinib·Prednisone
Chinese SLE Treatment And Research Group
Phase 4
180
Beijing, Guanzhou, Shenzhen, Nanning, Jiaozuo, Luoyang, Wuhan, Nanjing
2026-04-01
Recruiting
Can Perineal Post-Free Traction in Hip Arthroscopy Effectively Reduce Perineal Complications?
NCT07322705Femoroacetabular Impingement Syndrome
ChunBao Li
Not applicable
270
Beijing, Shenzhen, Luoyang, Nanjing, Xi'an, Taiโ€™an, Shanghai, Chengdu
2026-03-30
Recruiting
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
NCT07415551Allergic Diseases, Chronic Spontaneous Urticaria (CSU)
Yuhan Corporation
Phase 2
150
Guangzhou, Shenzhen
2026-03-26
Recruiting
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986Systemic Lupus Erythematosus (SLE)
DrugSG301
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
120
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guilin, Nanning
2026-03-26
Recruiting
Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia
NCT07388680Radiation-induced Lung Injury, Immune-related Pneumonia
DrugPirfenidone
Beijing Continent Pharmaceutical Co, Ltd.
Phase 2/3
298
Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Maoming, Shenzhen
2026-03-26
Recruiting
Fecal Microbiota Transplantation in Children With ASD
NCT07381374Autism Spectrum Disorder
Shenzhen Children's Hospital
Not applicable
1
Shenzhen
2026-03-21
Not yet open
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase โ…ก Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT07465120Moderate to Severe Atopic Dermatitis
DrugCMS-D001
Dermavon Holdings Limited
Phase 2
160
Beijing, Fuzhou, Guangzhou, Shenzhen, Haikou, Shijiazhuang, Tangshan, Zhengzhou
2026-03-20
Recruiting
Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma
NCT07692152Anal Squamous Cell Carcinoma, Limited-stage
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
350
Beijing, Shenzhen
2026-03-17
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Shantou, Shenzhen, Zhengzhou, Jingzhou, Wuhan
2026-03-16
Recruiting
Inactivated Bacteroides Fragilis for Prevention of Chemotherapy-Induced Diarrhea
NCT07309315Chemotherapy-induced Diarrhea
Shenzhen Hospital of Southern Medical University
Not applicable
200
Shenzhen
2026-03-13
Recruiting
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
NCT07362979Nasopharyngeal Cancinoma (NPC)
DrugsCCRT·GP·TP
Sun Yat-sen University
Phase 2
243
Dongguan, Guangzhou, Shenzhen, Zhanjiang
2026-03-12
Recruiting
Aortic No-Touch vs Partial Aortic Clamping in Off-Pump CABG
NCT07302659Coronary Artery Bypass Graft (CABG)
China National Center for Cardiovascular Diseases
Not applicable
380
Beijing, Qingdao, Shenzhen
2026-03-10
Not yet open
A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
NCT07298928Effectiveness
DrugTelitacicept
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
30
Shenzhen, Jinan, Hangzhou
2026-03-10
Recruiting
Acupressure for Cough in Lung Cancer Survivors
NCT07315672Lung Cancer (Diagnosis), Acupressure, Coughing, Symptom Cluster
The University of Hong Kong
Not applicable
80
Shenzhen
2026-03-09
Recruiting
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
NCT07502287Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
DrugsFludarabine·Cyclophosphamide
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
NCT07528066Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLC
Shanghai Chest Hospital
Observational
200
Fuzhou, Guangzhou, Shenzhen, Nanjing, Qingdao, Tianjing, Shanghai
2026-03-02
Recruiting
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
NCT07641036Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
DrugsFludarabine·Cyclophosphamide
Beijing Biotech
Phase 1/2
30
Shenzhen
2026-03-02
Recruiting
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
NCT07523529Advanced Unresectable, Metastatic
Beijing Biotech
Phase 1/2
72
Shenzhen
2026-03-02
Recruiting
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
NCT07627698Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
NCT07523542REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis
DrugsFludarabine·Cyclophosphamide
Beijing Biotech
Phase 1/2
24
Shenzhen
2026-03-02
Recruiting
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
NCT07500220Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
DrugsFludarabine·Cyclophosphamide
Beijing Biotech
Phase 1/2
30
Shenzhen
2026-03-02
Recruiting
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
NCT07641023Non-Small Cell Lung Cancer, Advanced/Metastatic
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
NCT07627711Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, Metastatic Disease
Beijing Biotech
Phase 1/2
42
Shenzhen
2026-03-02
Recruiting
Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma
NCT07510815Malignant Pleural Mesotheliomas
DrugsFludarabine·Cyclophosphamide
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
NCT07492628Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
DrugsFludarabine·Cyclophosphamide
Beijing Biotech
Phase 1
42
Shenzhen
2026-03-02
Recruiting
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
NCT07617805Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC
Beijing Biotech
Phase 1/2
42
Shenzhen
2026-03-02
Recruiting
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
NCT07589530Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
DrugFludarabine
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors
NCT07510828Advanced or Metastatic Solid Tumors
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
NCT07744256Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC
DrugEB-DART-NK01
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-03-02
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
NCT07551336Malignant Glioma, High-Grade Gliomas, Glioblastoma, Recurrent High-Grade Gliomas
Beijing Biotech
Phase 1
36
Shenzhen
2026-03-02
Recruiting
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
NCT07641049Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer, PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
DrugsFludarabine·Cyclophosphamide
Beijing Biotech
Phase 1
36
Shenzhen
2026-03-02
Recruiting
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
NCT07598955B2 Thymoma, Thymic Carcinoma
DrugsRimiducid·Fludarabine·Cyclophosphamide
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
NCT07551362Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
NCT07523555Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm
Beijing Biotech
Phase 1/2
96
Shenzhen
2026-03-02
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRฮฑ, MUC16) pt2
NCT07617753Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
NCT07589543Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
DrugsFludarabine·Cyclophosphamide
Beijing Biotech
Phase 1/2
42
Shenzhen
2026-03-02
Recruiting
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
NCT07622940Recurrent or Metastatic Esophageal Adenocarcinoma, Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-03-02
Recruiting
Hemi-tibial Plateau Osteotomy Combined With Arthroscopic Repair for Medial Meniscus Posterior Root Tears in Varus Knees
NCT07356674Knee Osteoarthristis, Meniscus Injury
Eighth Affiliated Hospital, Sun Yat-sen University
Not applicable
20
Shenzhen
2026-03-01
Not yet open
A Feasibility Study of Death Education Intervention for Family Caregivers of Advanced Cancer Patients
NCT07367984Palliative Care, Advanced Cancer, Family Caregivers
The Hong Kong Polytechnic University
Not applicable
30
Shenzhen
2026-03-01
Recruiting
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
NCT07467447Obesity
DrugRetatrutide
Hudson Biotech
Phase 2
300
Shenzhen
2026-02-15
Recruiting
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
NCT07487363Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction
Hudson Biotech
Phase 1/2
80
Shenzhen
2026-02-05
Recruiting
High-flow Nasal Cannula Versus Conventional Oxygen During Awake Tracheal Intubation With Difficult Airways
NCT07384494Awake Tracheal Intubation, Difficult Airway
Wenxian Li
Not applicable
336
Wuwei, Shenzhen, Baoding, Pizhou, Shanghai, Neijiang
2026-02-04
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRฮฑ, MUC16)
NCT07480954Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-02-04
Recruiting
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
NCT07480928Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease
Beijing Biotech
Phase 1/2
42
Shenzhen
2026-02-02
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
NCT07486089Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
NCT07467863Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC
Beijing Biotech
Phase 1/2
48
Shenzhen
2026-02-02
Recruiting
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
NCT07505745Prediabetes, Insulin Resistance, Overweight/Obesity
Hudson Biotech
Phase 2
120
Shenzhen
2026-02-02
Recruiting
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
NCT07551349Advanced or Metastatic Clear Cell Renal Cell Carcinoma
DrugFludarabine
Beijing Biotech
Phase 1/2
36
Shenzhen
2026-02-02
Recruiting
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
NCT07589517Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
Beijing Biotech
Phase 1/2
48
Shenzhen
2026-02-02
Recruiting
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
NCT07481747Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
DrugTirzepatide
Hudson Biotech
Phase 3
2,539
Shenzhen
2026-02-02
Recruiting
Topical GHK-Cu Gel for Acute Skin Wound Healing
NCT07437586Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)
Hudson Biotech
Phase 2
60
Shenzhen
2026-02-02
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
NCT07480941Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma
DrugsFludarabine·Cyclophosphamide
Beijing Biotech
Phase 1
36
Shenzhen
2026-02-02
Recruiting
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
NCT07481734Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis
Hudson Biotech
Phase 2
120
Shenzhen
2026-02-02
Recruiting
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
NCT07437560NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)
Hudson Biotech
Phase 2
60
Shenzhen
2026-02-02
Recruiting
BPC 157 for Acute Hamstring Muscle Strain Repair
NCT07437547Hamstring Muscle Strain, Skeletal Muscle Injury
Hudson Biotech
Phase 2
120
Shenzhen
2026-02-02
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
NCT07510802Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
NCT07480213Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage
DrugEB-DART-NK01
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of ฮฒ-TDT Patients
NCT07338344Transfusion-dependent ฮฒ-thalassemia Patients
DrugsThalidomide·Luspatercept
Rongrong Liu
Phase 2
78
Shenzhen, Baise City, Liuzhou, Yulin, Kunming, Naning
2026-02-01
Recruiting
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
NCT07462650Colorectal Cancer Metastatic, Adenocarcinoma of Colon
Beijing Biotech
Phase 1/2
48
Shenzhen
2026-02-01
Not yet open
Portal Vein Thrombosis in Cirrhosis: Incidence, Outcomes and Anticoagulation
NCT07422701Portal Vein Thrombosis, Liver Cirrhosis
Peking University First Hospital
Observational
2,522
Beijing, Shenzhen, Hengshui, Qinhuangdao, Wuxi, Qingdao
2026-02-01
Recruiting
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
NCT07374614Non-Small Cell Lung Cancer, ALK, Iruplinalkib, Lorlatinib
Peking University Shenzhen Hospital
Observational
20
Shenzhen
2026-01-31
Recruiting
Assessment of Food Intake Using Both 3D Scanning Method and a Photographic Method
NCT07371559Data Collection
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Observational
200
Shenzhen
2026-01-31
Recruiting
A Study of GC203 TIL in Advanced Solid Tumors (NF)
NCT07256756Solid Tumors, Adult
DrugGC203 TIL
Shanghai Juncell Therapeutics
Phase 1
8
Shenzhen
2026-01-30
Not yet open
Preventing Neurologic Complications in Valve Surgery
NCT07382362Left Atrial Appendage Closure
China National Center for Cardiovascular Diseases
Observational
100
Beijing, Qingdao, Shenzhen
2026-01-27
Active, closed
Time-Restricted Eating for Weight-Loss Maintenance
NCT07163455Overweight or Obese Adults
Harbin Medical University
Not applicable
500
Beijing, Chongqing, Shenzhen, Harbin, Xi'an, Qingdao, Weifang, Chengdu
2026-01-26
Recruiting
Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia
NCT07370519Androgenetic Alopecia (AGA)
DrugMinoxidil
Shenzhen People's Hospital
Phase 2
388
Shenzhen
2026-01-25
Not yet open
DragonFly M2 Pivotal Study
NCT07243197Mitral Valve (MV) Regurgitation
Hangzhou Valgen Medtech Co., Ltd
Not applicable
53
Shenzhen
2026-01-15
Recruiting
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
NCT07297212Recurrent Glioblastoma
DrugsPumitamig·Temozolomide·Bevacizumab
BioNTech SE
Phase 2
75
Beijing, Chongqing, Jinan, Shanghai, Shenzhen, Wuhan
2026-01-15
Recruiting
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
NCT07325539Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
Sun Yat-sen University
Phase 2
55
Guangzhou, Shenzhen
2026-01-12
Recruiting
International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
NCT07013461Nasopharyngeal Cancinoma (NPC)
The University of Hong Kong-Shenzhen Hospital
Observational
5,000
Shenzhen
2026-01-09
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
DrugsBMS-986504·Nab-paclitaxel·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 2/3
590
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2026-01-02
Recruiting
Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation
NCT07349498Hematopoietic Stem Cell Transplantation, Transplant Complication, Cardiovascular Events
Peking University People's Hospital
Observational
10,000
Beijing, Chongqing, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Xi'an
2026-01-01
Not yet open
Stereotactic Aspiration of Brain Stem Hematoma
NCT07300501Brain Stem Hematoma
First Affiliated Hospital of Zhejiang University
Not applicable
300
Hangzhou, Changsha, Guangzhou, Jinan, Shanghai, Shenzhen, Taizhou, Wenzhou
2026-01-01
Recruiting
Virtual Reality-based Sensory Stimulation for Delirium Prevention in Intensive Care Units
NCT07806422Delirium in the Intensive Care Unit
Chinese University of Hong Kong
Not applicable
300
Shenzhen
2026-01-01
Not yet open
Correcting Hypocapnia in Aneurysmal Subarachnoid Hemorrhage.
NCT07343232Aneurysmal Subarachnoid Hemorrhage (aSAH)
The Chinese University of Hong Kong, Shenzhen
Observational
80
Shenzhen
2026-01-01
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
DrugsFolfiri·Capox·Folfox·Pumitamig
Bristol-Myers Squibb
Phase 2/3
990
Hefei, Chongqing, Fuzhou, Fuzhou Fujian, Guangzhou, Shenzhen, Nanning, Tianjin
2025-12-31
Recruiting
Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne
NCT07366229Acne
Shenzhen People's Hospital
Phase 2
196
Shenzhen
2025-12-30
Recruiting
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
NCT07266116Systemic Light Chain Amyloidosis
DrugTQB2934
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
70
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guiyang, Baoding, Harbin
2025-12-26
Recruiting
Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial
NCT07194200Psoriasis, Lactobacillus Plantarum
Shenzhen People's Hospital
Phase 2
184
Shenzhen
2025-12-15
Recruiting
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
NCT07375316Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Osimertinib
Guangdong Association of Clinical Trials
Phase 2
120
Guangzhou, Meizhou, Shantou, Shenzhen
2025-12-15
Recruiting
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235Type 2 Diabetes
DrugIGlarLixi
Shanghai Zhongshan Hospital
Phase 4
1,316
Hefei, Huizhou, Shenzhen, Harbin, Xinxiang, Wuhan, Changsha, Hengyang
2025-12-13
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu
2025-12-11
Recruiting
Direct Visualization ERAT Versus Laparoscopic Appendectomy in Adults With Acute Uncomplicated Appendicitis
NCT07230379Acute Uncomplicated Appendicitis
Changhai Hospital
Not applicable
376
Chongqing, Guangzhou, Shenzhen, Kaifeng, Zhengzhou, Changsha, Suzhou, Nanchang
2025-12-10
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Beijing, Guangzhou, Shenzhen, Handan, Zhengzhou, Changsha, Jinan, Shanghai
2025-12-03
Recruiting
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
NCT06807281Atopic Dermatitis
DrugAbrocitinib
Pfizer
Phase 3
500
Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai
2025-12-02
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou
2025-12-02
Recruiting
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT07165951Metastatic Pancreatic Ductal Adenocarcinoma
DrugsAnlotinib hydrochloride·Gemcitabine Hydrochloride·Paclitaxel
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
566
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-12-02
Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031Chronic Graft Versus Host Disease
DrugBelumosudil
Sanofi
Phase 2
37
Beijing, Shanghai, Shenzhen, Suzhou
2025-12-02
Recruiting
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
NCT07282353Primary Biliary Cholangitis
DrugCS0159
Cascade Pharmaceuticals, Inc
Phase 3
135
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhanjiang, Nanning
2025-12-01
Recruiting
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
NCT07246564Myasthenia Gravis
UCB Biopharma SRL
Phase 4
40
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Jinan, Shanghai, Shenzhen
2025-12-01
By invitation
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
NCT03393962Ovarian Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2025-12-01
Not yet open
A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
NCT07292896Healthy Adults, Pulmonary Hypertension, Tricuspid Regurgitation, Heart Failure
First Hospital of China Medical University
Observational
2,640
Chongqing, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xiangyang, Changchun
2025-12
Rows per page Showing 101–200 of 576
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shenzhen?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 576 of those studies with a site in Shenzhen.

How many clinical trials are recruiting in Shenzhen?

337 of the 576 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 115 have not yet opened recruitment, 109 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.